Novo Nordisk A/S (NYSE:NVO) had its price target lifted by Bank of America from $355.00 to $400.00 in a report issued on Friday, BenzingaRatingsTable reports. Bank of America currently has a neutral rating on the stock.
A number of other analysts also recently commented on NVO. ValuEngine downgraded Novo Nordisk A/S from a hold rating to a sell rating in a research report on Tuesday, September 10th. Zacks Investment Research raised Novo Nordisk A/S from a sell rating to a hold rating and set a $50.00 target price for the company in a research report on Monday, July 15th. Jefferies Financial Group downgraded Novo Nordisk A/S from a hold rating to an underperform rating in a research report on Friday, August 30th. Pareto Securities raised Novo Nordisk A/S from a hold rating to a buy rating in a research report on Monday, August 5th. Finally, Deutsche Bank downgraded Novo Nordisk A/S from a buy rating to a hold rating and set a $52.42 target price for the company. in a research report on Thursday, June 20th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $159.65.
Shares of NVO opened at $49.48 on Friday. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $117.74 billion, a price-to-earnings ratio of 19.63, a PEG ratio of 2.12 and a beta of 0.57. The stock has a 50 day moving average of $50.85 and a 200 day moving average of $49.93. Novo Nordisk A/S has a 12 month low of $41.23 and a 12 month high of $53.55.
The company also recently announced a Semi-Annual dividend, which was paid on Tuesday, August 27th. Shareholders of record on Monday, August 19th were given a $0.318 dividend. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is currently 25.40%.
A number of large investors have recently added to or reduced their stakes in NVO. Clearbridge Investments LLC boosted its holdings in shares of Novo Nordisk A/S by 42.3% in the first quarter. Clearbridge Investments LLC now owns 1,160,942 shares of the company’s stock worth $60,729,000 after acquiring an additional 344,989 shares during the period. Jennison Associates LLC boosted its holdings in shares of Novo Nordisk A/S by 89.5% in the second quarter. Jennison Associates LLC now owns 1,229,986 shares of the company’s stock worth $62,778,000 after acquiring an additional 580,944 shares during the period. AE Wealth Management LLC bought a new position in shares of Novo Nordisk A/S in the second quarter worth $283,000. Mirova bought a new position in shares of Novo Nordisk A/S in the second quarter worth $49,000. Finally, GYL Financial Synergies LLC bought a new position in shares of Novo Nordisk A/S in the first quarter worth $1,090,000. 7.34% of the stock is owned by institutional investors and hedge funds.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Featured Article: Bull Market
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.